Cytosorbents (CTSO) Income towards Parent Company (2010 - 2026)

Cytosorbents (CTSO) has 17 years of Income towards Parent Company data on file, last reported at -$11.0 million in Q1 2026.

• Quarterly Income towards Parent Company fell 646.77% year-over-year to -$11.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$43.5 million (down 892.28% YoY) and the FY2025 annual result came in at -$6.8 million, up 24.49% from the prior year.
• Income towards Parent Company fell to -$11.0 million in Q1 2026, from -$4.1 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $4.2 million in Q4 2024 to a low of -$25.2 million in Q2 2025.
• A 5-year average of -$6.8 million and a median of -$6.1 million in 2023 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2023 — Income towards Parent Company plunged 700.76% — and 2024, when it surged 167.74%.
• Tracing CTSO's Income towards Parent Company over 5 years: stood at -$766126.0 in 2022, then slumped by 700.76% to -$6.1 million in 2023, then surged by 167.74% to $4.2 million in 2024, then sank by 198.46% to -$4.1 million in 2025, then tumbled by 169.79% to -$11.0 million in 2026.
• The last three Income towards Parent Company figures came in at -$11.0 million (Q1 2026), -$4.1 million (Q4 2025), and -$3.2 million (Q3 2025), per Business Quant data.